Biosimilar Product Differences Will Affect US Uptake, Amgen Predicts
Executive Summary
Differences in product characteristics should be considered in formulary decisions, Amgen says in annual trends report that puts its biosimilars in a strong competitive light while also bolstering the position of its reference biologics.
You may also be interested in...
A Look At Payers' Early Game Plans For Driving Biosimilar Use
Interviews with US payers suggest that at first they are more likely to focus on promoting biosimilars in treatment-naïve patients, as opposed to switching those on branded drugs, according to a new Datamonitor report.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.